Reuters logo
BRIEF-Exelixis' Cabozantinib meets key goal in late-stage trial
October 16, 2017 / 11:21 AM / a month ago

BRIEF-Exelixis' Cabozantinib meets key goal in late-stage trial

Oct 16 (Reuters) - Exelixis Inc

* Exelixis’ phase 3 celestial trial of Cabozantinib meets primary endpoint of overall survival in patients with advanced hepatocellular carcinoma

* Exelixis to submit a supplemental new drug application to U.S. Food and Drug Administration (FDA) in Q1 of 2018​

* Safety data in study were consistent with established profile of Cabozantinib​​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below